Sign in
CompletedPhase 3

The Safety and Efficacy of SYD-101 in Children With Myopia

Key facts

Who runs it
Sydnexis, Inc.
Where
Albuquerque, Bala-Cynwyd, Bangor, Boston, Buffalo, Chapel Hill, Charleston, Chicago, Colorado Springs, Cranberry Township, Danbury, Fargo, Fort Collins, Fort Lauderdale, Henderson, Indianapolis, Irwindale, Jupiter, Lakeway, Marietta, Medford, Munster, Ogden, Pasadena, Pittsburg, Raleigh, San Antonio, San Diego, Santa Barbara, Sunnyvale, Sweetwater, Tamarac, The Woodlands, Tigard, Virginia Beach, Washington, Waterbury, and Wilmette, United StatesSee the 41 sitesAlso in 2 other countries, 6 sites
Status
Completed
Phase
Phase 3
People taking part
852 people enrolled
Started
24 Apr 2019
Ended
1 May 2025
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • SYD-101 0.01%
  • SYD-101 0.03%
  • Vehicle
Record updated
30 July 2026

Who can take part

Age
3 years to 14 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Myopia of 0.5 D (diopters) to 6.00 D (inclusive) in both eyes
  • Astigmatism ≤1.50 D in both eyes
  • Anisometropia ≤1.00 D in both eyes
  • If myopia is ≥0.75 D, participant must be wearing single vision eyeglasses or soft, daily-wear, single-vision contact lenses that meet study investigator's criteria
  • BCVA (best-corrected visual acuity) Snellen equivalent of 20/32 or better

Who cannot take part

  • Current use of a monoamine oxidase inhibitor
  • History or evidence of ocular surgery or planned future ocular surgery in either eye; Other protocol-defined inclusion/exclusion criteria could apply
  • Participants with a history or current evidence of a medical condition predisposing them to degenerative myopia (e.g. Marfan syndrome, Stickler syndrome), or a condition that may affect visual function or development (e.g. diabetes mellitus, chromosome anomaly)
  • Evidence of any ocular inflammation or infection in either eye, including blepharitis, conjunctivitis, keratitis, and scleritis
  • Past, present or future plans to use orthokeratology (orthoK), rigid gas-permeable, bifocal, progressive-addition, multi-focal, or other lenses to reduce myopia progression; or the use of atropine, pirenzepine or other anti-muscarinic agent for myopia

Where in United States

Also in 2 other countries, 6 sites

  • Albuquerque, New MexicoHospital not named in the registry
  • Sie 136Bala-Cynwyd, United States
  • Bangor, MaineHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Buffalo, New YorkHospital not named in the registry
  • Chapel Hill, North CarolinaHospital not named in the registry
  • Charleston, South CarolinaHospital not named in the registry
  • Chicago, IllinoisHospital not named in the registry
  • Colorado Springs, ColoradoHospital not named in the registry
  • Cranberry Township, PennsylvaniaHospital not named in the registry
  • Danbury, ConnecticutHospital not named in the registry
  • Fargo, North DakotaHospital not named in the registry
  • Fort Collins, ColoradoHospital not named in the registry
  • Fort Lauderdale, FloridaHospital not named in the registry
  • Henderson, NevadaHospital not named in the registry
  • Indianapolis, IndianaHospital not named in the registry
  • Irwindale, CaliforniaHospital not named in the registry
  • Jupiter, FloridaHospital not named in the registry
  • Lakeway, TexasHospital not named in the registry
  • Marietta, GeorgiaHospital not named in the registry
  • Medford, OregonHospital not named in the registry
  • Munster, IndianaHospital not named in the registry
  • Ogden, UtahHospital not named in the registry
  • Ogden, UtahHospital not named in the registry
  • Pasadena, CaliforniaHospital not named in the registry
  • Pittsburg, KansasHospital not named in the registry
  • Raleigh, North CarolinaHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • San Diego, CaliforniaHospital not named in the registry
  • San Diego, CaliforniaHospital not named in the registry
  • Santa Barbara, CaliforniaHospital not named in the registry
  • Sunnyvale, CaliforniaHospital not named in the registry
  • Sweetwater, FloridaHospital not named in the registry
  • Tamarac, FloridaHospital not named in the registry
  • The Woodlands, TexasHospital not named in the registry
  • Tigard, OregonHospital not named in the registry
  • Virginia Beach, VirginiaHospital not named in the registry
  • Washington, MissouriHospital not named in the registry
  • Waterbury, ConnecticutHospital not named in the registry
  • Wilmette, IllinoisHospital not named in the registry

About the trial

What the trial wants to find out

Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lead to blindness. Early treatment of myopia in children could help slow the condition and minimize the risk of complications later in life. This study investigates the use of SYD-101, an eye solution, in slowing-down the progression of myopia in children.

The 3 groups in the trial

  • SYD-101 0.01%Treatment being tested

    1 drop in each eye at bedtime. Part 1: participants will be randomized to SYD-101 0.01% Part 2: participants will be re-randomized to SYD-101 0.01% or Vehicle

  • SYD-101 0.03%Treatment being tested

    1 drop in each eye at bedtime. Part 1: participants will be randomized to SYD-101 0.03% Part 2: participants will be re-randomized to SYD-101 0.03% or Vehicle

  • VehiclePlacebo, for comparison

    1 drop in each eye at bedtime. Part 1: participants will be randomized to Vehicle Part 2: participants will be re-randomized to SYD-101 0.03%

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-masked, Vehicle-controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children
Publications
Record updated
30 July 2026